Webinar: A first technology for counting adult tissue stem cells for applications in regenerative medicine and drug development

Available to view on demand. Presenting a solution for the longstanding unsolved problem of quantifying the number of stem cells in research and therapeutic tissue cell preparations.

Go to the profile of RegMedNet
Feb 24, 2016
0
0
Upvote 0 Comment



Since the first discovery of adult tissue stem cells, it has been impossible to count them. This conundrum persists because neither morphological nor molecular properties have been defined that distinguish tissue stem cells from more abundant committed progenitor cells. This webinar introduced AlphaSTEM, a first-in-class technology with the capability of counting homeostatic stem cells in complex research and therapeutic cell preparations from many different human tissues. The predicted impact of the AlphaSTEM stem cell counting technology on stem cell research, umbilical cord blood bank practice, hematopoietic stem cell transplantation therapies, gene-editing therapeutics , and drug candidate evaluations was considered.

What will you learn?

  • The nature of the adult tissue stem cell counting problem
  • How the AlphaSTEM stem cell counting technology works
  • How stem cell counting will impact tissue stem cell research
  • How the determination of “stem cell dose”, for the first time, will impact stem cell transplantation medicine, gene-editing therapeutics, and regenerative medicine research in general
  • How the ability to count tissue stem cells has already enabled assays that identify drug candidates that affect tissue stem cells, negatively, positively, or both

Who may this interest?

  • Research stem cell biologists, university and industry
  • Preclinical drug candidate evaluation CROs
  • Pharmaceutical companies (toxicologists, pharmacovigilance executives)
  • Hematopoietic stem cell transplantation physicians
  • Umbilical cord blood bank directors
  • Gene-editing therapeutic companies

Speaker


James L Sherley, MD, PhD

Founder and Director
Asymmetrex, LLC

James L Sherley is Director of stem cell medicine biotechnology company Asymmetrex, LLC. His education includes graduation from Harvard College in 1980 with a BA degree in Biology and from the Johns Hopkins University School of Medicine with combined MD/PhD degrees in 1988. After post-doctoral studies at Princeton University, he joined the Fox Chase Cancer Center as a principal investigator in 1991. His subsequent academic research career includes faculty positions at Massachusetts Institute of Technology and Boston Biomedical Research Institute. Dr Sherley’s research awards include Pew Biomedical Research Scholar, Ellison Medical Foundation Senior Scholar, and NIH Director’s Pioneer Award.


Additional Material from Asymmetrex

Counting, a "stem cell fundamental" for regenerative medicine - Jan 13

Counting to improve hematopoietic stem cell transplantation medicine - Jan 27

Counting to provide dosing for regenerative medicine - Feb 10

Counting to improve safety and reduce cost in drug development - Feb 24

Counting to accelerate progress in gene-editing therapeutics - Mar 9

For a full list of other webinars available on RegMedNet please see here.

Go to the profile of RegMedNet

RegMedNet

eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.